AlphAIAlphAI — Financial news for AI agents
investing.com$ATRC

BTIG raises AtriCure stock price target to $70 on strong Q3 results

BTIG raised its price target on AtriCure (ATRC) to $70 from $63, citing strong Q3 results. Revenue of $154.5M beat estimates, up 15.1% YoY. U.S. revenue grew 17%, while international revenue missed consensus. Adjusted EBITDA and EPS also exceeded expectations. AtriCure raised its 2026 revenue and earnings guidance. Shares are up 84% over the past year but may be overvalued, according to InvestingPro.

Original reporting
investing.com
Published Nov 4, 2026, 9:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ATRC
Bullish
high confidence
Mentioned
$ATRC
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ATRCBullishHigh
01

Why it matters

Earnings beat and guidance raise suggest improved operating performance and market confidence.

02

Market read

Earnings surprise and upgraded guidance are likely to attract short-term buying interest.

03

What to watch

Potential headwinds from regulatory scrutiny of cardiac devices are not discussed.

Relevance 7/10Novelty 8/10Timing: after-hours release

Background

AtriCure (NASDAQ:ATRC) is a medical device company focused on cardiac ablation technologies.

Company-level read

Ticker impact

$ATRCBullishHigh confidence
Context

BTIG raised its price target to $70 after AtriCure reported Q3 revenue beat, EPS beat and raised 2026 guidance.

Expected impact

upward pressure as the market prices in the higher target and guidance

Evidence & confidence

Revenue and EPS beat, plus guidance lift, are fresh material that typically lift the stock.

Market effects

Sector

Strong performance may lift other cardiac device makers in the medtech sector.

Regional

Minimal regional impact; primarily U.S. investors.

Global

Limited to medtech niche, no broad market effect.

Counterpoint

What could challenge this read

The stock may be overvalued at the new $70 target given modest absolute earnings.

Key entities

  • Analyst
    BTIG

    Raised price target to $70.

Read at source← All news

StoryAtriCure reports strong third-quarter results and raises 2026 guidance

Also covered by

2 outlets

Related articles

$ATRCMed

AtriCure 3Q 2026: Revenue $154.45M, EPS $0.08— 10-Q Summary

AtriCure reported Q3 2026 revenue of $154.45M, up 15% YoY, and net income of $4.06M, reversing a prior-year loss. EPS was $0.08 vs. a loss of $0.01. Nine-month revenue rose 14%, led by U.S. growth. Pain management and open ablation revenue increased, while hybrid procedures declined. New product launches and clinical trial updates were announced.

tradingview.com
$ATRCHigh

AtriCure (ATRC) Q3 2026 Earnings Call Transcript

AtriCure (ATRC) reported Q3 2026 revenue of $154.5M, up 15% YoY. Open ablation franchise grew 17%, driven by EnCompass Clamp adoption. Appendage management increased 12%, led by AtriClip FLEX-Mini. Pain management revenue surged 33%, with cryoSPHERE MAX and cryoXT driving growth. The company is on track with clinical trials, including BoxX-NoAF, which aims to address postoperative atrial fibrillation.

finance.yahoo.com
$ATRCHighAI 8/10

What AtriCure (ATRC) Said on Its Q3 Earnings Call

AtriCure (ATRC) reported Q3 earnings, highlighting 34.6% U.S. pain management revenue growth to $28.1M. The company expects 2026 revenue of $606M-$610M and raised adjusted EBITDA guidance to $91M-$94M. Clinical trials are progressing, with BoxX-NoAF enrollment nearing completion. International revenue grew 5.8% to $26.4M, despite some headwinds.

finance.yahoo.com
$ATRCHigh

AtriCure: Q3 Earnings Snapshot

AtriCure Inc. (ATRC) reported Q3 net income of $4.1M, or 8 cents per share, up from a loss last year. Adjusted EPS was 17 cents. Revenue hit $154.5M, beating estimates. The company forecasts full-year EPS of 40-46 cents and revenue of $606M-$610M. Shares are up 53% YTD and 77% over 12 months.

finance.yahoo.com
$ATRCHigh

AtriCure Reports Third Quarter 2026 Financial Results

AtriCure, Inc. (ATRC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 For immediate release November 3, 2026 AtriCure Reports Third Quarter 2026 Financial Results • Third Quarter 2026 worldwide revenue of $154.5 million, an increase of 15.0% year over year • Profitability expansion in the Third Quarter 2026, with net income of $4.1 mil

SEC EDGAR 8-K